Insights provides context and perspective about key pharmacy trends and issues

Icon of an infusion bag, overlaying a rising line graph
Specialty
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment and needs... More
Briefing
Icon of a syringe and dollar sign
Specialty
The specialty pipeline has many promising new drugs. The complexity and personalized nature of some medications require that they be managed under the medical benefit. More
Briefing
Icon of syringe, infusion bag and dollar sign tag
Specialty
The specialty pharmaceutical market continues to grow as a percentage of the overall prescription drug market, and its impact on payor trend also is rising. More
Feature
Icon of infusion bag and dollar bills
Specialty
Specialty spend under medical benefit is growing and a comprehensive medical benefit management strategy can help ensure appropriate utilization and control costs More
Feature
Icon of syringe and pills
Specialty
After a 19-year high for new drug approvals in 2015, 2016 saw a sharp decline. Including the six new biologics approved by the Center for Biologics Evaluation and Research (CBER), 2015 saw... More
Feature
Pills and female pharmacist icon
Specialty
The impact of specialty medications on payors’ trend is not only rising, it is doing so more rapidly than ever before. From 2010 to 2015, spending on specialty drugs doubled, accounting for... More
Feature
Icon of syringe and dollar tag
Specialty
Payors already dealing with the exploding cost of prescription medication — and specialty drugs in particular — are expected to face the budget impact sometime next year from at least one... More
Feature
Icon of Rx prescription script
Specialty
The U.S. Food and Drug Administration (FDA) approves drugs for specific indications, or uses. The indication identifies the condition(s) a drug is approved to treat, and it may also... More
Feature
Infusion bag icon
Specialty
Home infusion care provider convenience and better outcomes for patients while delivering cost savings for payors. More
Infographic
Icon of DNA double helix
Specialty
The Biologics Price Competition and Innovation (BPCI) Act of 2009 established a “shortened” pathway for two categories of biological products that are demonstrated to be biosimilar to, or... More
Feature